Can a pill shield ears from chemo damage?

NCT ID NCT05628233

Completed Prevention Sponsor: Sensorion Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug protects against damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SENS-401 (R-Azasetron Besylate)
What this could lead to: If it works, this could offer a way to protect hearing during cisplatin chemotherapy without reducing cancer treatment effectiveness.
What could go wrong: This is a small Phase 2a trial, so results may not confirm benefit. The drug could also have side effects or fail to prevent hearing loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEARING LOSS OTOTOXIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug-induced hearing loss neoplastic disease or syndrome platinum-induced ototoxicity prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEARING LOSS OTOTOXIC

Contacts and locations

Locations

Hôpital Henri Mondor

Créteil, 94010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.